State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
J Med Chem. 2023 Jul 27;66(14):9325-9344. doi: 10.1021/acs.jmedchem.3c00712. Epub 2023 Jul 13.
Oxidative stress has been implicated in a wide range of pathological conditions. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) exerts a central role in regulating the cellular defense system against oxidative and electrophilic insults. Nonelectrophilic inhibition of the protein-protein interaction (PPI) between Kelch-like ECH-associated protein 1 (Keap1) and Nrf2 has become a promising approach to activate Nrf2. Recently, multiple drug discovery strategies have facilitated the development of small-molecule Keap1-Nrf2 PPI inhibitors with potent activity and favorable drug-like properties. In this Perspective, we summarize the latest progress of small-molecule Keap1-Nrf2 PPI inhibitors from medicinal chemistry insights and discuss future prospects and challenges in this field.
氧化应激与广泛的病理状况有关。转录因子红细胞生成 2 相关因子 2(Nrf2)在调节细胞防御系统对抗氧化和亲电应激方面发挥着核心作用。Kelch 样 ECH 相关蛋白 1(Keap1)和 Nrf2 之间的蛋白质-蛋白质相互作用(PPI)的非亲电子抑制已成为激活 Nrf2 的一种有前途的方法。最近,多种药物发现策略促进了具有强大活性和良好类药性的小分子 Keap1-Nrf2 PPI 抑制剂的发展。在本观点中,我们从药物化学的角度总结了小分子 Keap1-Nrf2 PPI 抑制剂的最新进展,并讨论了该领域的未来前景和挑战。